A 12week, Randomized, Evaluator-Masked, Parallel Group Comparing Evening Dosing Of Xalacom Vs Cosopt In Subj W/ Glaucoma
Status:
Completed
Trial end date:
2006-07-01
Target enrollment:
Participant gender:
Summary
To demonstrate the statistical non inferiority of the combination of latanoprost and timolol
given in the evening time once a day vs the combination of dorzamalide and timolol twice a
day based on intraocular pressure measurements at 8 AM, 12 noon & 4 PM during a 12 week
treatment.
Phase:
Phase 4
Details
Lead Sponsor:
Pfizer Pfizer's Upjohn has merged with Mylan to form Viatris Inc.